Skip to main content
Reviews Epitalon

The eye studies and the wider Epithalon record

Open questions

Epithalon questions: safety, sleep and claims

These are the questions left over after the striking results have had their turn.

Epithalon side effects

The retinitis pigmentosa series and the 2007 pineal-peptide report described no adverse effects. The female C3H/He mouse study also reported no toxic effects during the experiment. This is a small human safety record, with no controlled long-term assessment to establish rare or delayed risks.

Community accounts mention soreness, redness or bruising, occasional headache or lightheadedness, and drowsiness or vivid dreams. These are anecdotal accounts rather than clinical evidence; causation is unverified. The research review cannot settle their frequency or the long-term safety question.

A safety verdict needs a fuller human record than these reports supply. The cancer-cell telomere findings give a specific reason for careful follow-up, alongside the broader gaps in human safety testing.

FDA status of Epitalon

The FDA has not approved Epithalon for any illness in the United States. Research-labelled Epitalon is still sold, while the compounded medicine has no FDA approval.

The FDA safety-risk list places Epitalon in its table of substances with withdrawn nominations, following its earlier Category 2 listing. That withdrawal grants neither drug approval nor Category 1 status; the FDA still describes safety concerns.

For patients in the United States alone, Promise Peptides offers prescription peptide care on mypromise.com. Its licensed U.S. clinician considers each request and sometimes declines; its available options are specific to both the patient's state and the treatment.

The FDA still has not approved Epitalon for any illness. A prescription decision does not confer FDA approval on a compounded product.

A research label doesn't mean a product passed medicine checks. It also doesn't prove that the bottle matches its label.

Rules for purchase differ outside Russia and may be unclear. Russia has used Epithalamin, a mixed pineal-gland extract, for much longer.

A lawful sale would not prove that Epitalon works or is safe. Legal status and medical worth are separate matters.

The world sports drug agency bars athletes from unapproved drugs. Epitalon falls under that broad ban.

Does Epithalon improve sleep?

Hormone rhythms changed in older monkeys given Epitalon and in elderly people given the parent extract Epithalamin. Direct sleep outcomes remain untested for Epitalon in this record. Reports of better sleep sit beside reports of no noticeable effect. Both are anecdotal.

I’d welcome sleep measurements as eagerly as a replication of the eye findings. The sleep discussion explains the distinction in the experimental record.

Cosmetic claims

The oral stem-cell study measured cellular aging markers, and the telomere experiment measured chromosome ends in cell lines. Neither measured wrinkles, hair color or how old a person looked. That leaves the cosmetic claim without a controlled human outcome to support it.

How quickly might a change appear?

The 2025 cell experiment used different exposure periods for cancer and normal cells. That timing records laboratory observations. It establishes no reliable time at which a person would feel a benefit. The half-life page also explains why a frequently repeated clearance estimate has no measured human basis.

Longevity verdict

The fly experiment and mouse survival study justify continued investigation. No randomized human trial in this record establishes a longevity benefit. The human retinal series concerns vision in people with a particular disease.

My verdict stays narrow: laboratory activity is well worth studying, and the human claims remain much larger than the clinical evidence. A review can take promising results seriously while leaving its final score unwritten.